tbuckley/cabot-search huggingface dataset:
ENDOSCOPIC MANAGEMENT OF EARLY COLORECTAL CANCER: COMPARISON BETWEEN PIECEMEAL MUCOSECTOMY AND HYBRID SUBMUCOSAL DISSECTION IN A SINGLE TERTIARY MEDICAL CENTRE IN NORTHERN ITALY
Authors: E Viale, GF Bonura, A Podda, C Notaristefano, PA Testoni
Journal: Endoscopy (2018)

Gastrointestinal early neoplasm exceeding 20 mm in diameter are often be removed with piecemeal endoscopic mucosal resection (PEMR), but it seems to increase the risk of recurrence. Endoscopic submucosal dissection (ESD) is an alternative procedure to enable en-bloc resection with a lower local recurrence but, its technical difficulties, its longer procedure time and increased risk of perforation limit its widespread. To overcome these issues it has been developed a new hybrid technique: hybrid ESD (ESD-H), a simplified ESD (used also as a rescue procedure in difficult colorectal ESD cases). The main aim of our study was to analyze recurrence rate lesions after removing early stage of colorectal lesions ≥30 mm removal in a single, tertiary-care, centre employing ESD-H or PEMR. Safety, duration of procedures were analyzed too.
SPY-GLASS: RETROSPECTIVE STUDY ABOUT ITS INDICATIONS, AND DIAGNOSTIC AND THERAPEUTIC PERFORMANCE IN A TERTIARY HOSPITAL
Authors: K Cárdenas-Jaén, JA Casellas, F Ruiz, L Compañy, JF Martínez, JR Aparicio
Journal: Endoscopy (2018)

The new SpyGlass DS system allows to perform cholangioscopy/pancreatoscopy with digital direct vision, and to develop diagnostic and therapeutic measures with a single operator. Our aim is to analyze the indications for use of the Spy-Glass DS system in our hospital, and its diagnostic and therapeutic utility.
ZENKER DIVERTICULUM TREATMENT: RETROSPECTIVE COMPARISON OF FLEXIBLE ENDOSCOPIC WINDOW TECHNIQUE AND SURGICAL APPROACHES
Authors: L Calavas, M Pioche, J Rivory, JC Saurin, S Roman, T Ponchon
Journal: Endoscopy (2018)

Different therapeutic options exist for symptomatic Zenker diverticulum. During flexible endoscopy we add a technical trick called the “window technique” to improve the field of view. We evaluated the flexible endoscopy window technique to ENT surgical approaches, open cervicotomy or rigid endoscopy in terms of effectiveness and safety.
Solitary Asymptomatic Tumor in the Axilla
Authors: Konstantin Dumann, Jan C. Simon, Mirjana Ziemer
Journal: JAMA Dermatology (2018)

A woman in her 60s presented with a solitary, indolent, erythematous plaque in the right axilla and also reported a slowly growing subcutaneous node with progressive infiltration of the overlying skin. What is your diagnosis?
Is EUS with Doppler Comparable to Transabdominal Ultrasond as a Screening Test for Chronic Mesenteric Ischemia (CMI)?
Authors: KW Noh, S Pungpapong, MB Wallace, TA Woodward, M Al-Haddad, T Federici, M Raimondo
Journal: Endoscopy (2006)

Aims: EUS has been proposed as a single test to evaluate persistent upper abdominal pain. CMI, a potential cause of pain, has not been previously evaluated by EUS. As Doppler flow in the celiac artery (CA) and superior mesenteric artery (SMA) can be measured, we propose that EUS can be used to screen for CMI. Doppler transabominal ultrasound (TUS) is the standard screening test for CMI. Methods: Pts with chronic abdominal pain with suspicion of CMI undergoing either EUS or TUS were reviewed. The peak systolic velocity (PSV) of the CA and SMA were recorded. If MRA was performed, the findings were compared with the values obtained during EUS or TUS. MRA results were considered to be the gold standard when available. Alternatively, a negative TUS and EUS was considered to be an alternative negative gold standard. κ statistics were used to compare the agreement of findings between each modality. Results: 42 pts were included (EUS-38, TUS-24, MRA-22). Doppler measurements of the CA and SMA were successful in 100% and 76% of cases, respectively. EUS and TUS had comparable accuracies evaluating the presence of abnormally elevated flow in the CA and SMA (85% vs. 88%, 96% vs. 95%). EUS and TUS had moderate concordance with MRA. When either the CA or SMA was positive, EUS had a higher sensitivity over TUS (80% vs. 67%) in predicting the presence of stenosis. In addition, 19 EUS examinations yield alternative or additional diagnoses. Discussion: Doppler measurements of the CA and SMA can be obtained during EUS examination. The results suggest that EUS measurements of the CA and SMA are as reliable as TUS when screening for CMI. EUS has an advantage over TUS as it can yield alternative disorders that may be contributing to chronic abdominal pain. EUS with Doppler has the potential to be used as a single comprehensive test in the evaluation of persistent upper abdominal pain.
Indication des coloscopies: les recommandations de l'ANAES sont elles bien suivies? Résultats d'une enquête régionale
Authors: A Michaud-Herbst, V Jouhet, P Ingrand, JC Letard, JP Dupuychaffray, M Morichau-Beauchant
Journal: Endoscopy (2009)

Introduction: En avril 2004, l'ANAES a publié des recommandations de bonne pratique concernant les indications de l'endoscopie digestive basse en dehors du dépistage en population et de la surveillance des sujets à risque. A notre connaissance, le respect de ces recommandations n'a pas étéévalué sur une large cohorte. Nous avons confronté ces recommandations à la pratique des gastroentérologues des établissements publics et privés.
NARROW-BAND IMAGING (NBI) VERSUS LUGOL CHROMOENDOSCOPY IN THE DETECTION OF OESOPHAGUS SQUAMOUS NEOPLASMS IN A HIGH-RISK POPULATION: A REAL-LIFE RANDOMISED CONTROLLED MULTICENTRE TRIAL
Authors: M Gruner, A Denis, C Masliah, M Amil, E Metivier-Cesbron, D Luet, M Kaasis, E Coron, M Le Rhun, S Lecleire, M Antonietti, JL Legoux, L Lefrou, P Renkes, AL Tarreirrias, P Balian, P Rey, B Prost, C Cellier, G Rahmi, S Elia, S Fratte, B Guerrier, S Touzet, T Ponchon, M Pioche
Journal: Endoscopy (2018)

Narrow-Band Imaging (NBI) is as sensitive as Lugol chromoendoscopy to detect oesophageal squamous cell carcinoma (SCC) and appears more specific than Lugol chromoendoscopy in expert centres but its specificity in current practice is not known. This study aimed to prove the superiority of NBI specificity over Lugol chromoendoscopy to detect oesophageal SCC and high-grade dysplasia (HGD) in current practice (including tertiary care centres, local hospitals and private clinics).
Meta-analysis of cancer risk among users of insulin glargine.
Authors: Alice Koechlin, Mathieu Boniol, Chris Robertson, Geremia Bolli, Julio Rosenstock, Peter Boyle
Journal: Journal of Clinical Oncology (2012)

1510 Background: The association between diabetes, its risk factors and treatments, and cancer risk and death is now high on the clinical and research agenda. Methods: All data regarding cancer risk and use of insulin glargine has been assembled and meta-analyses performed using state-of-the-art statistical methodology. Glargine is the most studied insulin in this regard. A random effects model was employed with tests for heterogeneity (I 2 ) and publication bias. These meta-analyses are based on reports from epidemiological studies involving a total of 907,008 diabetic subjects and 2,597,602 person-years of observation. Results: Based on independent estimates from 14 studies, the Summary Relative Risk (SRR) for all forms of cancer was (SRR=0.90, 95% CI (0.82, 0.98)) and for breast cancer SRR=1.14 (95% CI (1.00, 1.29)). For new users of glargine, from 7 studies, the SRR for breast cancer was SRR=1.20 (95% CI (0.90, 1.58)). Based on independent estimates for 9 studies, for colorectal cancer the SRR was 0.73 (95% CI (0.59, 0.91)) and for prostate cancer SRR=1.16 (95% CI (1.03, 1.30)). Overall, the risk of developing cancer among users of insulin glargine is reduced compared to the risk of users of other insulins. Similarly, the risk of colorectal cancer is reduced among users of glargine. While above unity, the risks of breast cancer and prostate cancer are increased marginally. Potential limitations to this meta-analysis include that the comparison group was not the same in all studies but this could also be seen as a strength. This is not likely to invalidate the findings of this analysis nor would the fact that different adjustments were made in the individual studies. Conclusions: The current evidence gives no support to the hypothesis that insulin glargine is associated with an increased risk of cancer as compared to other insulins and should give reassurance to physicians and their patients. Given the short exposure time possible to glargine (less than 5 years maximum), it is not biologically plausible to have a causal link to common forms of cancer.
Abstract 027: Life-course Cardiovascular Risk Mobility in the International Childhood Cardiovascular Cohort (i3C) Consortium
Authors: Benjamin D Pollock, Tian Hu, Olli T Raitakari, Trudy L Burns, Alan R Sinaiko, Costan G Magnussen, Elaine M Urbina, Jessica G Woo, Julia Steinberger, Markus Juonala, Alison Venn, Stephen R Daniels, Terry Dwyer, David R Jacobs, Lydia A Bazzano
Journal: Circulation (2018)

Background: We previously adapted a methodology from literature on socioeconomic mobility (the “American Dream”) to develop an analogous concept of Cardiovascular (CV) Risk Mobility (CRM: movement across CV risk rankings during aging) in the Bogalusa Heart Study (BHS). We found high mobility, such that childhood CV risk burden tracks into adulthood, but not so strongly that a low CV-risk stratum in adulthood is unreachable. Because geopolitical, ethnic, and healthcare differences may affect mobility in life course CV health, we sought to further test CRM using an international consortium. Methods: We used prospective data from n=20,685 children followed into adulthood (inverse probability weighted, n=6,029 with adult follow-up) from the 1970s-2010s in three of the i3C Consortium cohorts: BHS, the Young Finns Study (YFS), and the Muscatine Study. During childhood (age 5-18 yr), participants were percentile-ranked by their CV risk factor burden using an age- and sex-adjusted sum of z-scores from total cholesterol, systolic blood pressure, BMI, and triglycerides. During adult follow-up (age 40-55 yr), participants were percentile-ranked using the Framingham score. The rank-rank slope (β) from the regression of adult/child percentile rankings forms the measure of CRM. Results: Patterns of CRM were similar to BHS in both YFS [β=.15 (95% CI: .12, .18) at age 10] and Muscatine [β=.14 (95% CI: .09, .19) at age 10]. Pooled results of age/rank interaction were significant ( p =0.005), indicating a pattern of lower CRM (more tracking) earlier in childhood. The pooled β=.15 (95% CI: .14, .16)], meaning that a child ranked 10 percentiles better was only 1.5 percentiles better as an adult. Conclusions: Populations in the developed world track, yet exhibit large mobility in CV risk. Children are readily able to move from both high to low and low to high CV risk strata over the life course. The earlier children develop a high CV risk factor burden relative to their peers, the lower their mobility, or opportunity to “catch up,” into adulthood.
EUS-GUIDED RADIOFREQUENCY ABLATION (RFA) FOR PANCREATIC PREMALIGNANT TUMOR: A NEW HOPE?
Authors: M Barthet, M Gasmi, JM Gonzalez, M Giovannini
Journal: Endoscopy (2018)

Pancreatic NET and IPMN with worrisome features required surgical resection due to the respective risk of lymph nodes/metastatic widespread or invasive adenocarcinoma. The aim of this prospective study was: primary endpoint, to evaluate the safety of EUS-RFA in such pancreatic tumors; secondary endpoint: to assess the efficacy in a one year follow-up.
Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i>-Rearranged Cancers
Authors: Alexander Drilon, Romel Somwar, Biju P. Mangatt, Henrik Edgren, Patrice Desmeules, Anja Ruusulehto, Roger S. Smith, Lukas Delasos, Morana Vojnic, Andrew J. Plodkowski, Joshua Sabari, Kenneth Ng, Joseph Montecalvo, Jason Chang, Huichun Tai, William W. Lockwood, Victor Martinez, Gregory J. Riely, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Christopher Matheny, Ryma Benayed, Natasha Rekhtman, Marc Ladanyi, Gopinath Ganji
Journal: Cancer Discovery (2018)

Abstract NRG1 rearrangements are oncogenic drivers that are enriched in invasive mucinous adenocarcinomas (IMA) of the lung. The oncoprotein binds ERBB3–ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic paradigm of ERBB3/ERBB2 inhibition. As proof of concept, a durable response was achieved with anti-ERBB3 mAb therapy (GSK2849330) in an exceptional responder with an NRG1-rearranged IMA on a phase I trial (NCT01966445). In contrast, response was not achieved with anti-ERBB2 therapy (afatinib) in four patients with NRG1-rearranged IMA (including the index patient post-GSK2849330). Although in vitro data supported the use of either ERBB3 or ERBB2 inhibition, these clinical results were consistent with more profound antitumor activity and downstream signaling inhibition with anti-ERBB3 versus anti-ERBB2 therapy in an NRG1-rearranged patient-derived xenograft model. Analysis of 8,984 and 17,485 tumors in The Cancer Genome Atlas and MSK-IMPACT datasets, respectively, identified NRG1 rearrangements with novel fusion partners in multiple histologies, including breast, head and neck, renal, lung, ovarian, pancreatic, prostate, and uterine cancers. Significance: This series highlights the utility of ERBB3 inhibition as a novel treatment paradigm for NRG1-rearranged cancers. In addition, it provides preliminary evidence that ERBB3 inhibition may be more optimal than ERBB2 inhibition. The identification of NRG1 rearrangements across various solid tumors supports a basket trial approach to drug development. Cancer Discov; 8(6); 686–95. ©2018 AACR. See related commentary by Wilson and Politi, p. 676. This article is highlighted in the In This Issue feature, p. 663
ACCURACY OF KI-67 MEASUREMENT ON EUS-FNA CYTOLOGICAL SAMPLES VS SURGICAL SPECIMENS: A SINGLE CENTRE EXPERIENCE
Authors: S Rizza, L Venezia, P Cortegoso Valdivia, M Bruno, S Gaia, CG De Angelis
Journal: Endoscopy (2018)

The number of pre-operative EUS-FNA for suspected pancreatic neuroendocrine tumors (pNETs) is increasing. EUS-FNA provides pre-operative cytological diagnosis and information about the biological behaviour of the neoplasia. Measurement of Ki-67 expression on EUS-FNA specimen is feasible, but it is still undefined how this measure could reflect the value of Ki-67 expression assessed on surgical specimens. We report our single center experience, describing the feasibility of measurement of Ki-67 expression on cytological samples and evaluating its accuracy in comparison to Ki-67 expression on surgical specimens, with the purpose of demonstrating the reliability of EUS-FNA for guiding, alone, the clinical management of patients unfit for surgery.
Résultats du traitement médical et endoscopique des hémorragies ulcéreuses avec caillot adhérent
Authors: F Fein, G Piton, S Koch, AC Dupont Gossard, M Nachury, JP Cervoni, F Carbonnel
Journal: Endoscopy (2009)

Introduction: Le traitement des hémorragies ulcéreuses avec caillot adhérent (stade 4 de la classification de Forrest) est controversé.
The 2017 AHA/ACC Performance and Quality Measures for Patients With Acute Myocardial Infarction
Authors: Hani Jneid, Biykem Bozkurt, Gregg C. Fonarow
Journal: JAMA Cardiology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
Authors: Kim Anna Reiss, Joseph M. Herman, Marianna Zahurak, Anthony W. Fyles, Michael F. Milosevic, Angela Scardina, Caitlin Joffe, Emily Petito, Amy Hacker-Prietz, Alice P. Chen, Sarah Madhu Temkin, Naomi Horiba, Robert J. Kinders, Lihua Wang, Lee-Anne Stayner, Nilofer Saba Azad
Journal: Journal of Clinical Oncology (2016)

2584 Background: Combining low-dose radiation therapy with poly (ADP-ribose) polymerase (PARP) inhibition has been shown to enhance anti-tumor efficacy through potentiating DNA damage in tumor cells. We combined low dose fractionated whole abdominal radiation (LDFWAR) with escalating doses of veliparib (ABT-888), an orally available, small molecule PARP inhibitor, in patients (pts) with peritoneal carcinomatosis from advanced solid tumor malignancies with a dose escalation in ovarian and fallopian cancer patients (OV). Methods: Pts were treated with escalating doses of veliparib, 40-400mg PO BID on days on days 1-21 of 3 28-day cycles on 6 dose levels. LDFWAR consisted of 21.6Gy in 36 fractions, 0.6 Gy twice daily on days 1 and 5 for weeks 1-3 of each cycle. Circulating tumor cells (CTCs) were serially collected. Quality of life (QoL) was assessed using the EORTC-QLQ-C30 questionnaire. Results: 32 pts were treated. Median follow-up was 45 months (10-50). The most common treatment-related gr3 and 4 toxicities were lymphopenia (59%), anemia (9%), thrombocytopenia (12%), neutropenia (6%), leukopenia (6%), nausea (6%), diarrhea (6%), anorexia (6%), vomiting (6%) and fatigue (6%). The MTD was determined to be 250mg PO BID (DL5). Median PFS was 3.6mo and median OS was 9.1mo. Survival on OV was not significantly longer than those with other cancers (9.4mo compared to 8.8mo, p = 0.885). QoL decreased for all groups during treatment, but was not seemingly worse at higher dose levels and the negative impact seemed to be less profound in OV patients. BRCA status was known for 14/18 patients with OV cancers. Conclusions: Veliparib plus LDFWAR is moderately well tolerated with gastrointestinal symptoms, fatigue and myelosuppression being the most common toxicities. In this very small study, BRCA mutation status did not appear to have an impact on PFS or OS of OV patients. DL5 (veliparib 250mg PO BID) is the RP2D for any future studies. Clinical trial information: NCT01264432. PFS median, mo OS median, mo ALL PATIENTS (n = 32) 3.63 9.05 OV (n = 18) 2.73 9.35 BRCA+ (n = 5) 1.77 8.96 BRCA- (n = 9) 3.66 8.03
NOTES abdominal exploration: a prospective comparative study of laparoscopy, transgastric NOTES and transcolonic NOTES in a porcine model
Authors: SN Shaikh, G Fernandez-Esparrach, M Ryou, M Ryan, P Sylla, A Cohen, M Ferrigno, DW Rattner, CC Thompson
Journal: Endoscopy (2008)

Aim: To evaluate the procedural differences and outcomes measures between laparoscopic, transgastric NOTES (TG), and transcolonic NOTES (TC).
Depression Screening in Dermatology—Think Isotretinoin
Authors: Kory Patrick Schrom, Eliot N. Mostow, Terri Nagy
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Ninety-minute daratumumab infusion is safe in multiple myeloma
Authors: Hallie Barr, Jessica Dempsey, Allyson Waller, Ying Huang, Nita Williams, Nidhi Sharma, Don M. Benson, Ashley E. Rosko, Yvonne A. Efebera, Craig C. Hofmeister
Journal: Leukemia (2018)
Augmentation du volume de l'estomac proximal après insertion de ballons intra-gastriques
Authors: S Layec, D Heresbach, A Chauvin, B Janson, S Guérin, CH Malbert
Journal: Endoscopy (2009)

Introduction: Le ballon intra-gastrique, rempli avec de l'air ou du sérum physiologique, est proposé dans la prise en charge de l'obésité avec une efficacité variable selon les sujets. Des modifications des propriétés mécaniques de la paroi gastrique, liées à la présence du ballon, pourraient expliquer certains échecs du traitement. L'objectif était d'évaluer l'évolution du volume gastrique et les modifications de la compliance de la paroi de l'estomac après insertion, pendant 5 mois, de ballons intra-gastriques dans l'estomac de porcs miniatures.
Abstract 12214: Cardiorespiratory Fitness Lowers the Risk of Stroke in African-American Veterans
Authors: Peter Kokkinos, Charles Faselis, Puneet Narayan, Jonathan Myers, Apostolos Tsimploulis, Marshall Balish, Michael Doumas, Andreas Pittaras, Liam Philiben, Pamela Karasik, Hans Moore
Journal: Circulation (2016)

Introduction: Stroke incidence is significantly higher in African-Americans (AA) than in any other racial group. Cardiorespiratory fitness (CRF) is associated with a more favorable cardiovascular health. The CRF-stroke incidence association has not been fully explored in AA patients. Hypothesis: We hypothesize that the CRF-stroke incidence association will be inverse and graded. Methods: From 1985 to 2014, we identified 13,511 AA (mean age: 58±11) with a normal response to an exercise tolerance test (ETT) and no prior history of stroke. We established five fitness categories based on age-stratified quintiles of peak metabolic equivalents (MET) achieved: Least-Fit (4.2±1.2 METs; n=2,708); Low-Fit (6.0±1.2; n=2,914); Moderate-Fit (7.9±1.0 METs; n=2,816); Fit (8.6±1.4 METs; n=2,903); and High-Fit (11.5±2.3 METs; n=2,170). Multivariable Cox model, adjusted for age, BMI, gender, cardiac risk factors, blood pressure, sleep apnea, alcohol dependence and medications, was used to estimate hazard ratios (HR) and 95% confidence intervals [CI], for incidence of stroke across fitness categories. The Least-fit category was used as the reference group. Results: During follow-up (median=11.3 years) 703 individuals (5.2%) developed stroke. The risk for stroke was 7% lower for each 1-MET increase in exercise capacity (HR=0.93, CI: 0.90-0.96; p&lt;0.001). When considering fitness categories, stroke risk was lower by: 27% (HR=0.73; CI: 0.59-0.89) in the Low-Fit individuals; 34% (HR= 0.66; CI: 0.53-0.74) in the Moderate-Fit; 41% lower in the Fit (HR= 0.59; CI: 0.45-0.75) and 43% in High-Fit individuals (HR= 0.57; CI: 0.44-0.74). Conclusions: CRF was inversely related to stroke incidence in AA. The risk declined progressively with increasing CRF and was over 40% lower for individuals in the two highest fitness categories.